Last updated 23 days ago

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

413 patients around the world
Available in United States, Brazil
AstraZeneca
413Patients around the world
This study is for people with
Gastric cancer
Requirements for the patient
To 130 Years
All Gender
Medical requirements
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy